Yield10 Bioscience Inc
Yield10 Bioscience, Inc. operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. Its products include Camelina oil for production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA); and for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, … Read more
Yield10 Bioscience Inc (YTEN) - Total Liabilities
Latest total liabilities as of June 2024: $9.21 Million USD
Based on the latest financial reports, Yield10 Bioscience Inc (YTEN) has total liabilities worth $9.21 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yield10 Bioscience Inc - Total Liabilities Trend (2002–2023)
This chart illustrates how Yield10 Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yield10 Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Yield10 Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adventure Box Technology AB
ST:ADVBOX
|
Sweden | Skr15.06 Million |
|
Hansard Global Plc
LSE:HSD
|
UK | GBX1.33 Billion |
|
Skillcast Group PLC
LSE:SKL
|
UK | GBX9.15 Million |
|
Fingerprint Cards AB (publ)
OTCGREY:FGRRF
|
USA | $54.60 Million |
|
United Royale Holdings Corp
OTCQB:URYL
|
USA | $44.13K |
Liability Composition Analysis (2002–2023)
This chart breaks down Yield10 Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yield10 Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yield10 Bioscience Inc (2002–2023)
The table below shows the annual total liabilities of Yield10 Bioscience Inc from 2002 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $6.39 Million | +73.41% |
| 2022-12-31 | $3.69 Million | -16.04% |
| 2021-12-31 | $4.39 Million | -12.04% |
| 2020-12-31 | $4.99 Million | -76.01% |
| 2019-12-31 | $20.80 Million | +186.46% |
| 2018-12-31 | $7.26 Million | +114.85% |
| 2017-12-31 | $3.38 Million | -22.81% |
| 2016-12-31 | $4.38 Million | +7.86% |
| 2015-12-31 | $4.06 Million | -6.43% |
| 2014-12-31 | $4.34 Million | -31.56% |
| 2013-12-31 | $6.34 Million | +2.76% |
| 2012-12-31 | $6.17 Million | -85.80% |
| 2011-12-31 | $43.45 Million | +0.82% |
| 2010-12-31 | $43.09 Million | +1.38% |
| 2009-12-31 | $42.51 Million | +12.30% |
| 2008-12-31 | $37.85 Million | +27.02% |
| 2007-12-31 | $29.80 Million | +65.49% |
| 2006-12-31 | $18.01 Million | -66.58% |
| 2005-12-31 | $53.88 Million | +15.92% |
| 2004-12-31 | $46.48 Million | +1195.45% |
| 2002-12-31 | $3.59 Million | -- |